SCHEMBL30008730

SCHEMBL30008730

Clc1ccc(CNc2ccc(-c3ncnc4[nH]ccc34)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 3/20 0.55
JAK2 O60674 4/20 0.54
TTBK1 Q5TCY1 3/20 0.53
TTBK2 Q6IQ55 3/20 0.53
JAK1 P23458 1/20 0.52
FLT3 P36888 3/20 0.51
PDGFRB P09619 1/20 0.51
KIT P10721 1/20 0.51
MAP3K19 Q56UN5 1/20 0.51
MAPT P10636 2/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
IKBKB O14920 1/20 0.50
CHUK O15111 1/20 0.50
JAK3 P52333 3/20 0.48
GSK3B P49841 3/20 0.48
AURKA O14965 2/20 0.48
DAPK3 O43293 2/20 0.48
PRKD3 O94806 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009157 0.87 BTK (0.55) BTKJAK2TTBK1TTBK2FLT3
SCHEMBL15661177 0.86 JAK2 (0.70) BTKJAK2TTBK1TTBK2JAK1
SCHEMBL20752269 0.80 JAK2 (0.60) BTKJAK2JAK1FLT3PDGFRB
SCHEMBL30008724 0.78 JAK2 (0.52) BTKJAK2FLT3PDGFRBIKBKB
SCHEMBL16793627 0.78 JAK2 (0.66) BTKJAK2JAK1FLT3PDGFRB
SCHEMBL30009483 0.77 KIT (0.67) JAK1KITIKBKBCHUKAURKB
SCHEMBL24805255 0.75 IKBKB (0.65) BTKJAK2JAK1FLT3PDGFRB
SCHEMBL30009347 0.75 JAK2 (0.55) BTKJAK2JAK1FLT3PDGFRB
SCHEMBL15660156 0.75 BTK (0.57) BTKJAK2TTBK1TTBK2JAK1
SCHEMBL21044826 0.74 JAK2 (0.60) BTKJAK2JAK1FLT3PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 BTK 236/4885JAK2 61/4885TTBK1 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.